Epithalon Where to Buy: A Specification Beside Every Figure

Epithalon where to buy is a question about documents long before it is a question about sellers, so the documents get graded first. Six criteria below, all fixed before any storefront was opened, and every one of them phrased so a certificate can fail it.

The reason to write them down in advance is not tidiness. Buying criteria invented after the shopping tend to describe whatever the preferred seller happens to do well, and a reader cannot tell the difference from outside. Fixed criteria can be disagreed with, which is the only useful property a buying framework has.

Epithalon where to buy: the six criteria, and what each one rules out

Each criterion is paired with the failure it detects, because a criterion that cannot name a failure is a preference. The order is by dependency rather than importance: a criterion sits earlier when failing it makes everything below it unverifiable rather than merely weaker.

Column three is the one worth rereading. Each criterion buys a specific piece of information and nothing beyond it, and the habit of treating a good certificate as a general reassurance is how a purity figure ends up standing in for four tests that were never run.

Why a figure without a specification is an observation, not a result

The second criterion does more work than it looks like it should. A percentage printed on its own cannot pass or fail anything, because passing requires a threshold that the number could have fallen short of. Put a specification beside it and the same figure becomes a claim with consequences: the laboratory has committed to a line, and the result either clears it or does not.

This matters more for net content than for purity, and almost nobody applies it there. A label reading 10 mg is a nominal quantity, not a measurement, and a specification of 10 mg with a tolerance of 10 percent either way is a commitment that the true weight will fall between 9 and 11 mg. Once that band is written down, a measured figure inside it is a pass and a measured figure outside it is a failure, and a buyer can work out what the tolerance costs at its worst point rather than assuming the label. Without the band there is nothing to work out, because there is no measurement and no boundary, only a printed number on a box.

The six criteria applied to batch 15-05260628

One Epithalon report can be quoted in full, which is one more than most of this market offers. Report KVR-2026-A36FF4, issued by Kovera Labs for Ascension Peptides and certified 23 May 2026, covers batch 15-05260628 of a lyophilised 10 mg presentation, red cap, silver crimp, molecular formula C14H22N4O9, CAS 307297-39-8. The formula and CAS number both match what PubChem holds for CID 219042 at a molecular weight of 390.35, so the substance described on the page is the tetrapeptide Ala-Glu-Asp-Gly rather than something adjacent to it.

Criterion one passes: the batch number appears on the report and is the number a buyer can ask to see on the vial. Criterion two passes: purity is reported as 99.312 percent against a written specification of not less than 98 percent, which is the shape the criterion requires. Criterion four passes, and it is the interesting one: net content is reported as 9.64 mg against a specification of 10 mg with a tolerance of 10 percent either way. That is inside the band and under the printed figure, and it is the only line on the page that reads slightly against the seller.

Criterion five passes on coverage: an endotoxin safety screen against a limit of 0.5 EU/mL is recorded, alongside a microbial sterility screen returning no growth, and a heavy metals block covering arsenic, cadmium, lead and mercury. That combination is uncommon enough in research peptide supply to be worth naming, because the two microbiological tests are the ones that speak to the hazard a regulator has actually described for this class of substance rather than to a general notion of quality.

Criterion six passes. Kovera Labs is named as the issuing laboratory, the report carries its own number and a per-report access code, it prints a verification address at koveralabs.com so the document can be checked against the issuer rather than against the seller who published it, and it is signed by a named lab director rather than issued anonymously. Somebody has put their name to it, which is the difference between a document with an author and a table with a logo. Criterion three fails outright, and that is the next section.

Two numbers and five words, which is the real shape of the page

Count what the certificate actually reports. Purity is a number. Net content is a number. Identity is the word Epithalon, given as the result of an LC-MS comparison against a reference standard also given as Epithalon. The endotoxin screen is the word PASS. The sterility screen is the phrase no growth. Each of the four heavy metals is the word negative. Two measured values, and the rest reported as verdicts.

A verdict is not worthless. Somebody ran a test, applied a criterion and recorded an outcome, and that is a great deal more than a page which never mentions the test. But a verdict cannot be re-examined. Identity confirmed by LC-MS with no expected mass, no measured mass and no spectrum is a conclusion a reader has to accept, where a printed pair of masses near the 390.35 that PubChem records would be a measurement a reader could check. An endotoxin line reading PASS establishes that the result sat under 0.5 EU/mL and hides how far under, which is the difference between a comfortable margin and a near miss. A heavy metals result reading negative gives no detection limit, and negative below an unstated limit is a weaker statement than a concentration below a printed one.

Here is the part worth sitting with. The two lines that carry real numbers are purity, which flatters the vendor, and net content, which does not. A document that summarised everything into verdicts could very easily have summarised the fill weight into a tick as well, and it did not. That is a small signal about how the paperwork is handled, and small signals are most of what a buyer has. It also runs the opposite way from the neighbouring Selank lot on the same storefront, which assayed 12.29 mg against a 10 mg label, a case worked through in our page on a quantity result that contradicts the listing. Over the label and under the label are both news, and only a supplier that runs the test can deliver either.

The one criterion that is not documentary, and what it is worth

Domestic stock belongs on a buying list, and it belongs there for a duller reason than most pages give. It is not a quality signal. A vial held in a warehouse two states away is neither purer nor better characterised than the same vial held overseas. What it changes is the number of uncontrolled steps between the batch report and the bench: fewer border crossings, fewer transfers, a shorter and more predictable transit, and a return path that exists in practice rather than in theory.

Treat a stated dispatch commitment as a claim like any other. The vendor disclosed on this page states same day dispatch on orders placed before 2pm CST, which is a domestic timezone commitment rather than a warehouse audit, and the way to test it is the tracking record on an actual order rather than the sentence on the listing. What the criterion buys is recourse, and recourse is the thing that quietly disappears in the channels covered in our comparison of how far each supply channel can document a batch.

What clearing five of the six criteria does not establish

A certificate answers what is in the vial. It has nothing to say about what the contents do in a person, and for this compound the gap between those two questions is unusually wide. FDA writes that compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, that it has not identified safety-related information regarding epitalon for the proposed route of administration, and that it therefore lacks sufficient information to know whether the drug would cause harm if administered to humans. That is not a warning about a specific harm. It is a statement that the file is empty.

The regulatory position is also narrower than either side of this market tends to claim. Epitalon was nominated for the 503A bulks list and placed in category 2 under the interim policies, and the nomination was then withdrawn, so it now appears on FDA’s safety risks page under the heading covering substances previously in category 2 that were withdrawn. It is absent from all three categories of the nominated list updated 14 May 2026. A page telling you it is currently category 2 is quoting a status it no longer holds, and a page telling you it is banned has invented one.

The published research is the other half of the honest answer. The English-language literature on this tetrapeptide is animal, cell and in vitro work, much of it from one Russian group, including a 2025 review in the International Journal of Molecular Sciences collecting the claims made for it. Telomere and longevity effects are what the compound is marketed on; they are claims made by identifiable researchers in identifiable papers rather than settled results, and a search of ClinicalTrials.gov returns no registered study with epitalon, epithalon or AEDG peptide as an intervention. A well-documented batch and an empty human evidence base are not in tension, because they answer different questions, and only one of those questions has a certificate. For the wider version of that distinction, see our primer on what a research-use designation certifies and what it does not.